Aspirin Resistance in Coronary Artery Disease

Completed · Early Phase 1

Conditions studied: Coronary Artery Disease

In brief

The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certain patient characteristics associate with aspirin resistance. In addition, we will compare the effects of enteric-coated aspirin and chewable aspirin.

Key facts

Study ID

NCT00753935

Run by

Vanderbilt University

People needed

92

Starts

2006-06-01

Expected to finish

2014-03-01

Last updated by the study team

2018-04-19

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• On aspirin 81-325mg daily at time of enrollment
• Documented stable coronary artery disease or > 6 months after coronary artery bypass grafting or interventional cardiac procedure
• Written informed consent

You may not qualify if…

• Pre-menopausal female
• Renal disease (creatinine >= 2 mg/dl)
• Anemia (Hematocrit < 30%)
• Thrombocytopenia (platelet count < 135,000/ul)
• Use of NSAIDs or coxibs within the previous 2 weeks
• Concurrent use of other anti-platelet agents
• Uncontrolled hypertension (systolic BP > 180 mmHg)
• Decompensated congestive heart failure
• Recent coronary syndrome (< 6 months)
• History of significant GI bleeding

Where it is running

• Vanderbilt University — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.